SCHEMBL23273663

SCHEMBL23273663

CCOC(=O)c1cnn(C2CC2)c1Br

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.47
OPRK1 P41145 1/20 0.43
RAB9A P51151 3/20 0.43
NPC1 O15118 3/20 0.43
KDM4E B2RXH2 2/20 0.43
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 6/20 0.42
HPGD P15428 2/20 0.42
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
PDE4B Q07343 2/20 0.41
PLAT P00750 1/20 0.41
TSHR P16473 2/20 0.41
KMT2A Q03164 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2671108 0.94 LMNA (0.48) LMNAOPRK1RAB9ANPC1KDM4E
SCHEMBL23289754 0.91 PDE4B (0.48) LMNAPDE4B
SCHEMBL1063097 0.90 LMNA (0.42) LMNAOPRK1RAB9ANPC1KDM4E
SCHEMBL23289755 0.88 LMNA (0.44) LMNAOPRK1RAB9ANPC1KDM4E
SCHEMBL13887500 0.85 LMNA (0.49) LMNARAB9ANPC1KDM4EHSD17B10
SCHEMBL27869185 0.85 CYP3A4 (0.43) LMNAOPRK1RAB9ANPC1KDM4E
SCHEMBL1059761 0.85 LMNA (0.56) LMNAALDH1A1KMT2ASMN1; SMN2MEN1
SCHEMBL1061726 0.85 GPR119 (0.45) LMNAKDM4EHSD17B10ALDH1A1HPGD
SCHEMBL30984273 0.84 LMNA (0.48) LMNARAB9ANPC1KDM4EHSD17B10
SCHEMBL23122360 0.83 LMNA (0.47) LMNARAB9ANPC1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114761397-B Benzodiazepine derivatives for the treatment of Respiratory Syncytial Virus (RSV) infection 辉瑞公司 2024-11-05 CN disclosed
US-20220409629-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION PFIZER INC. 2022-12-29 US disclosed
US-20220409629-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION PFIZER INC. 2022-12-29 US disclosed
EP-4048665-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION Reviral Limited (GB) 2022-08-31 EP disclosed
CN-114761397-A Benzodiazepine derivatives for the treatment of Respiratory Syncytial Virus (RSV) infection 瑞威有限公司 2022-07-15 CN disclosed
WO-2021079121-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION ReViral Limited (GB) 2021-04-29 WO disclosed
WO-2021079121-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION ReViral Limited (GB) 2021-04-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220409629-A1 BENZODIAZEPINE DERIVATIVES FOR TREATING A RESPIRATORY SYNCYTIAL VIRUS (RSV) INFECTION GABRA1, GABRA3, CNR1 LMNA 2278/4885OPRK1 149/4885RAB9A 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.